Welcome to Otsuka America Pharmaceutical, Inc.

Contact us | Search Site | Site Map

This is a spacer image

Contact:

Corporate Communications
or by mail:
Corporate Communications
Otsuka America Pharmaceutical, Inc.
2440 Research Boulevard
Rockville, MD 20850 USA


Font Size:

May 21, 2009

FDA Approves SAMSCA� (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia

May 5, 2009

American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health

March 4, 2009

American Psychiatric Foundation Announces Recipients of Helping Hands Grants

February 25, 2009

Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka�s Pharmaceutical Business Worldwide

February 12, 2009

Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer

September 4, 2008

September 4, 2008: Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration

September 4, 2008

September 4, 2008: Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye

August 26, 2008

Otsuka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic

May 8, 2008

U.S. Food and Drug Administration Approves ABILIFY� (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features

May 6, 2008

American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health - Supported by a Grant from Otsuka America Pharmaceutical, Inc.

April 1, 2008

American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants - Support by a Grant from Otsuka America Pharmaceutical, Inc.

April 1, 2008

American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants - Supported by a Grant from Otsuka America Pharmaceutical, Inc.

February 29, 2008

U.S. Food and Drug Administration Approves ABILIFY� (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

November 20, 2007

U.S. Food and Drug Administration Approves ABILIFY� (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

November 15, 2007

ABILIFY� (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration

November 6, 2007

U.S. Food and Drug Administration Approves ABILIFY� (aripiprazole) for Adolescent Patients with Schizophrenia

October 2, 2007

Meretek Diagnostics, Inc. and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger

August 14, 2007

American Psychiatric Foundation Announces Recipients of 2007 Awards for Advancing Minority Mental Health

December 12, 2006

ABILIFY� (aripiprazole) Injection for Intramuscular Use For Adults with Agitation Associated with Schizophrenia or Bipolar Mania Now Available

December 7, 2006

ABILIFY� (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults with Bipolar I Disorder Following Treatment For a Recent Manic or Mixed Episode

September 7, 2006

Helping Hands Grants Support Community Mental Health Programs, Funded by Otsuka America Pharmaceutical, Inc.

August 17, 2006

Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY� DISCMELT� (aripiprazole)

May 30, 2006

American Psychiatric Foundation Announces Recipients of 2006 Awards for Advancing Minority Mental Health - Supported by a Grant from Otsuka America Pharmaceutical, Inc.

May 25, 2006

Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care in Management of Community-Treated Patients with Schizophrenia

May 16, 2006

ABILIFY^� (aripiprazole) Demonstrated Efficacy as Maintenance Therapy in Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode

March 13, 2006

American Psychiatric Foundation Announces Recipients of Inaugural�Helping Hands Grants -� Supported by a Grant by Otsuka America Pharmaceutical, Inc.

February 7, 2006

Bristol-Myers Squibb Company and Otsuka Pharmaceutical, Co., Ltd.� Announce Availability of 2mg (aripiprazole) Tablet and Nonrefrigerated Oral Solution

August 18, 2005

American Psychiatric Foundation’s Awards for Advancing Minority Mental Health Is Seeking Applicants for its 2005 Program

August 15, 2005

Otsuka Announces Support of Helping Hands Grant Program

June 1, 2005

Otsuka Celebrates 20 Successful Years In Maryland

May 25, 2005

New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia

May 18, 2005

Multiple Studies at DDW Report on Adacolumn^� Apheresis Device in Treating Inflammatory Bowel Disease

April 26, 2005

Otsuka America Pharmaceutical, Inc. Launches National and Local Initiatives to Eliminate Minority Health Disparities

April 1, 2005

Hiromi Yoshikawa, Chairman and CEO of Otsuka America Pharmaceutical, Inc. Joins PhRMA Board of Directors

March 23, 2005

American Psychiatric Foundation Announces 2004 Recipients of Awards for Advancing Minority Mental Health

March 7, 2005

Abilify^®(aripiprazole) Granted Approval for New Indication

January 4, 2005

FDA Provides Oral Solution Formulation of Abilify^® (aripiprazole)

December 21, 2004

American Heart Association Presents Arteriosclerosis/Heart Failure Research Prize.

October 7, 2004

Otsuka America Pharmaceutical, Inc. Enters Co-Promotion Alliance with Santarus, Inc

October 1, 2004

FDA Approves Abilify^® (aripiprazole) for Treatment of Acute Bipolar Mania, Including Manic and Mixed Episodes

September 21, 2004

Terry Prime Promoted to Vice President, Marketing of Otsuka America Pharmaceutical, Inc.

September 15, 2004

Otsuka America Pharmaceutical, Inc. Receives Frost & Sullivan’s 2004 Product Innovation of the Year Award for Antipsychotic Medications

August 10, 2004

Otsuka’s Adacolumn^®Device to Enter Pivotal Study in Crohn’s Disease

May 18, 2004

Data Presented at Digestive Disease Week on Two Otsuka Products in Development for Inflammatory Bowel Disease

May 5, 2004

New Data and Analyses Demonstrate Abilify^� (aripiprazole) Effective at Treating Patients with Acute Manic and Mixed Episodes of Bipolar Disorder

May 5, 2004

Clinical Study Shows Intramuscular Administration of Aripiprazole (Abilify^�) Significantly Improves Acute Agitation in Patients with Schizophrenia

April 13, 2004

American Psychiatric Foundation Presents First-Ever Minority Mental Health Awards

April 7, 2004

Otsuka's Adacolumn^� Device to Enter Pivotal Study in Ulcerative Colitis

November 14, 2003

Study Shows 40 Percent Relative Risk Reduction in Coronary Stent Blockage with Cilostazol Added to Standard Therapy

September 8, 2003

FDA Approveds Abilify � (aripiprazole) Supplemental New Drug Application (sNDA for Maintaining Stability in Patients with Schizophrenia

July 16, 2003

Supplemental New Drug Application Submitted for Abilify (aripiprazole) for the Treatment of Acute Bipolar Mania

May 20, 2003

Results from New Clinical Studies: Aripiprazole Significantly Improved Symptoms of Acute Bipolar Mania

May 19, 2003

Aripiprazole Demonstrates Better Weight Change Profile, Comparable Efficacy in Schizophrenia Compared to Olanzapine in New Study

May 12, 2003

Otsuka Teams with American Psychiatric Foundation for New Minority Mental Health Awards Program

February 25, 2003

Supplemental New Drug Application (sNDA) for Long-Term Schizophrenia Treatment Submitted for Abilify (aripirprazole)

* OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.

0109W-0602